彭布罗利珠单抗
尿路上皮癌
佐剂
医学
肿瘤科
癌
转移性尿路上皮癌
内科学
癌症研究
病理
癌症
膀胱癌
免疫疗法
作者
Andrea B. Apolo,Karla V. Ballman,Guru Sonpavde,Stephanie Berg,William Y. Kim,Rahul Atul Parikh,Min Yuen Teo,Randy F. Sweis,Daniel M. Geynisman,Petros Grivas,Gurkamal Chatta,Zachery R. Reichert,Joseph W. Kim,Mehmet Asım Bilen,Bradley A. McGregor,Parminder Singh,Abhishek Tripathi,Suzanne Cole,Nicholas I. Simon,Scot A. Niglio
标识
DOI:10.1056/nejmoa2401726
摘要
Among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival was significantly longer with adjuvant pembrolizumab than with observation. (Funded by the National Cancer Institute of the National Institutes of Health and others; Alliance A031501 AMBASSADOR ClinicalTrials.gov number, NCT03244384.).
科研通智能强力驱动
Strongly Powered by AbleSci AI